GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Percheron Therapeutics Ltd (ASX:PER) » Definitions » Book Value per Share

Percheron Therapeutics (ASX:PER) Book Value per Share : A$0.02 (As of Dec. 2023)


View and export this data going back to 2001. Start your Free Trial

What is Percheron Therapeutics Book Value per Share?

Percheron Therapeutics's book value per share for the quarter that ended in Dec. 2023 was A$0.02.

During the past 12 months, Percheron Therapeutics's average Book Value Per Share Growth Rate was -25.00% per year. During the past 3 years, the average Book Value Per Share Growth Rate was 18.60% per year. During the past 5 years, the average Book Value Per Share Growth Rate was 19.40% per year. During the past 10 years, the average Book Value Per Share Growth Rate was -6.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Percheron Therapeutics was 66.00% per year. The lowest was -41.30% per year. And the median was -16.15% per year.

Percheron Therapeutics's current price is A$0.074. Its book value per share for the quarter that ended in Dec. 2023 was A$0.02. Hence, today's PB Ratio of Percheron Therapeutics is 4.93.

During the past 13 years, the highest P/B Ratio of Percheron Therapeutics was 11.07. The lowest was 0.64. And the median was 2.09.

Warning Sign:

Percheron Therapeutics Ltd stock PB Ratio (=4.17) is close to 2-year high of 4.29


Percheron Therapeutics Book Value per Share Historical Data

The historical data trend for Percheron Therapeutics's Book Value per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Percheron Therapeutics Book Value per Share Chart

Percheron Therapeutics Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Book Value per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 0.01 0.01 0.03 0.02

Percheron Therapeutics Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Book Value per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.04 0.03 0.02 0.02 0.02

Competitive Comparison of Percheron Therapeutics's Book Value per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Percheron Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Percheron Therapeutics's PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Percheron Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where Percheron Therapeutics's PB Ratio falls into.



Percheron Therapeutics Book Value per Share Calculation

Percheron Therapeutics's Book Value Per Share for the fiscal year that ended in Jun. 2023 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(9.98-0.00)/669.32
=0.01

Percheron Therapeutics's Book Value Per Share for the quarter that ended in Dec. 2023 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(16.45-0.00)/901.55
=0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.

Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.


Percheron Therapeutics  (ASX:PER) Book Value per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


Percheron Therapeutics Book Value per Share Related Terms

Thank you for viewing the detailed overview of Percheron Therapeutics's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Percheron Therapeutics (ASX:PER) Business Description

Traded in Other Exchanges
Address
14 Wallace Avenue, Toorak, VIC, AUS, 3142
Antisense Therapeutics Ltd is a drug manufacturer. The company is engaged in research and development of novel antisense pharmaceuticals. The company operates in two segments that have been identified based on its antisense oligonucleotide products as ATL1102 and ATL1103.

Percheron Therapeutics (ASX:PER) Headlines

No Headlines